Skip to main content
. 2020 Oct 8;14(6):746–754. doi: 10.5009/gnl20114

Table 3.

Detailed Review of Patients Treated with EVAC

Patient No. Sex/age, yr SEMS before EVAC Operation TNM stage/ pathology Size of leak, cm Success to closure Duration of SEMS, day Duration of EVAC, day EVAC change Follow-up, day Stricture within 1 yr
1 M/68 Yes PG with DTR T1bN0
AWD
2.0 Yes 46 16 Yes 362 No
2 M/56 Yes TG with RY T1bN0
AMD
2.1 Yes 6 15 No 361 No
3 M/74 Yes PG with DTR T1bN0
AMD
2.5 Yes 12 21 Yes 523 No
4 M/55 Yes PG with DTR T1aN0
AMD
3.0 Yes 21 6 No 748 No
5 M/58 Yes PG with DTR T1bN0
APD
3.3 Yes 38 15 Yes 718 Yes
6 M/80 Yes TG with RY T4N3
APD
2.0 Yes 16 23 Yes 530 No
7 M/81 Yes STG-BI T1bN1
APD
3.0 Yes 12 13 No 246 No
8 F/65 No STG-BI T1aN0
SRC
2.0 Yes NA 6 No 27 No
9 M/63 No STG-BI T1bN0
AMD
2.5 Yes NA 13 No 367 No
10 F/68 No STG-BII T4N3
APD
2.0 Yes NA 17 Yes 30 No
11 M/70 No STG-BI G3N0
NET
1.5 Yes NA 6 No 55 No

EVAC, endoscopic vacuum-assisted closure; SEMS, self-expandable metallic stent; M, male; F, female; PG, proximal gastrectomy; DTR, double tract reconstruction; TG, total gastrectomy; RY, Roux-en Y esophagojejunostomy; STG-BI, subtotal gastrectomy with gastroduodenostomy; STG-BII, subtotal gastrectomy with gastrojejunostomy; AWD, adenocarcinoma, well-differentiated; AMD, adenocarcinoma, moderately differentiated; APD, adenocarcinoma, poorly differentiated; SRC, signet ring cell carcinoma; NET, neuroendocrine tumor; NA, not available.